

## Palivizumab (Synagis)

## **Prior Authorization Form/Prescription**

\_\_ Date Medication Required: \_ Ship to: O Physician O Patient's Home O Other\_

Phone: 866-399-0928 F	ax: 8//-386-4	4695						
Patient Information								
Last Name:	First Name:		me:		Middle:	DOB:		
Address:				City:			State:	Zip:
Daytime Phone:			Evening Phone: Sex: [			Sex:	Male F	emale
Patient's Mother's Name an	d DOB:							
Insurance Information (	Attach copies	of cards)						
Primary Insurance:				Secondary Insurance:				
ID# Group#				ID# Group#				
City: State:				City:			State:	
Physician Information								
Name:	Sp	pecialty: NPI:						
Address:			City:		State: Zip:		ip:	
Phone #: Secure Fax #:			Fax #:	Office Contact:				
Home Healthcare Agency Name and Contact Information (if applicable):								
Primary Diagnosis								
ICD-10 Code:   Chronic lung disease of prematurity (bronchopulmonary dysplasia)   Congenital heart disease   Anatomic pulmonary abnormalities   Neuromuscular disorder   Profoundly immunocompromised   Cystic fibrosis   Other:								
Prescription Information								
MEDICATION	STRENGTH			DIRECTIONS			QUANTITY	REFILLS
Synagis (palivizumab)								
Clinical Information	***	** Please su	bmit supportir	ng clinical docume	entation ****	k		
INITIAL THERAPY	CONTI	NUATION O	F THERAPY;	Therapy start da	te:			
<ol> <li>Has patient had a positive response to the prescribed therapy?</li></ol>								
Complete this section O  7. Is patient an Alaska nati 8. Will patient be profound chemotherapy, severe of the profound chemotherapy.  9. If preterm birth or chromatical characteristics and the profound disease of the profound disease of the profound characteristics. Has patient requires the profound characteristics in the profound characteristics in the profound characteristics.  Supplemental of the profound characteristics are profound characteristics.	ve or American dly immunocom combined immunocom inic lung disease of prematurity, > 21% oxygen for any of the follow	Indian? []\ promised duri nodeficiency, of prematuri or at least 28 coming within	Yes No  Ing the RSV sease  Chronic granulon  Ity, please docun  days after birth?  6 months of the	natous disease)?   nent patient's gestar Yes   No	Yes No tional age:	wee	eks(	days
		an one system	nic corticosteroic	d therapy 🔲 🗀 🗅	Diuretic therapy		ontinue to pag	



Physician's Signature \_\_\_

## Palivizumab (Synagis) Prior Authorization Form/Prescription

DAW

Date:	Date Medication Required:			
Ship to: O Physician O Patient's Home O Other				

## Phone: 866-399-0928 Fax: 877-386-4695 11. If congenital heart disease, does any of the following apply to patient? Yes \*\*Mark all that apply\*\* Acyanotic heart disease Medication to control congestive heart failure required Cardiac surgical procedure required Moderate to severe pulmonary hypertension Cyanotic heart defect and RSV prophylaxis is recommended by pediatric cardiologist Undergoing cardiac transplantation or cardio-pulmonary bypass during the current RSV season **Patient Name:** DOB: 12. If anatomic pulmonary abnormalities or neuromuscular disorder, does patient have impaired ability to clear secretions from the upper airways (e.g., due to ineffective cough)? Yes No 13. If cystic fibrosis, a. Does patient have manifestations of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable)? b. Is patient's weight for length < 10<sup>th</sup> percentile? Yes No c. Is there clinical evidence of nutritional compromise? Yes No d. Has patient been diagnosed with chronic lung disease of prematurity? Yes No Complete this section ONLY for indications other than those listed above: 14. Has patient tried and failed, or is contraindicated to, accepted standards of care? Yes No \*\*If yes, submit documentation and answer the following:\*\* a. Please list all previous therapies:

Date:

b. Was patient adherent to previously tried therapies? Yes No No, patient intolerant to drug